Ask Warren

Seoul Pharma

018680 · KOSDAQ · ₩018680 · 서울제약

₩1,782▼ ₩102 (5.41%)End-of-day · Oct 29, 2026 · End-of-day prices.
Trade
Alert me
SellBuy
AnnualQuarterly

Income statement

Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024
Revenue₩12B₩12B₩14B₩14B₩12B₩13B₩14B₩13B
Cost of sales₩4.6B₩4.9B₩5.7B₩5.6B₩4.3B₩5.1B₩5.3B₩5.8B
Gross profit₩7.2B₩7.2B₩7.9B₩8B₩7.7B₩7.8B₩8.6B₩7.6B
Operating income−₩343M−₩186M−₩217M−₩34M−₩914M−₩115M₩629M₩70M
Net income−₩318M−₩192M−₩1.9B₩4.1B−₩1.3B−₩164M₩1.5B−₩692M
Net income to shareholders−₩318M−₩192M−₩1.9B₩4.1B−₩1.3B−₩164M₩1.5B−₩692M

Balance sheet

Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024
Total assets₩68B₩71B₩72B₩74B₩73B₩71B₩72B₩67B
Current assets₩32B₩34B₩34B₩36B₩34B₩32B₩32B₩28B
Cash and equivalents₩17B₩18B₩9.9B₩7.5B₩10B₩5.7B₩7.5B₩7.4B
Total liabilities₩28B₩30B₩31B₩33B₩34B₩31B₩31B₩28B
Current liabilities₩22B₩14B₩15B₩16B₩17B₩14B₩14B₩11B
Borrowings₩3B₩15B₩10B₩15B₩15B₩13B₩10B₩10B
Total equity₩41B₩41B₩41B₩41B₩39B₩40B₩40B₩40B
Shareholders' equity₩41B₩41B₩41B₩41B₩39B₩40B₩40B₩40B

Cash flow

Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024
Cash from operations₩892M₩8.6B₩2.9B−₩2.7B₩2.1B−₩444M−₩2.9B−₩1.7B
Capital spending₩22M₩334M₩371M₩117M₩89M₩284M₩54M₩897M
Free cash flow₩870M₩8.3B₩2.5B−₩2.8B₩2B−₩728M−₩3B−₩2.6B

Consolidated where available. Amounts in won.

Also known as: Seoul Pharma / 서울제약 / 018680 / KRX:018680

Source: KRX statistical information